Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Andrea Varga, Monica M. Mita, Jennifer J. Wu, John J. Nemunaitis, Timothy Francis Cloughesy, Paul S. Mischel, Johanna C. Bendell, Kent C. Shih, Luis G. Paz-Ares, Amit Mahipal, Jean-Pierre Delord, Robin Katie Kelley, Jean-Charles Soria, Lilly Wong, Shuichan Xu, Angela James, Xiaoling Wu, Rajesh Chopra, Kristen Hege, Pamela N. Munster
Institutions: Institut Gustave Roussy, Cedars-Sinai Medical Center, New York University, Mary Crowley Cancer Research Center, University of California, Los Angeles, Tennessee Oncology, Hospital Universitario Virgen del Rocío, Moffitt Cancer Center, Institut Claudius Regaud, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Celgene (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2600107601